Due to recent advances in electron paramagnetic resonance imaging (EPRI) technology, in vivo localization of a single tissue based on unique physiology, has become a real possibility. EPRI could be a powerful imaging modality to define tumor boundaries, detect metastatic lesions, and report tissue-specific physiological information. The Human Epidermal Growth Factor Receptor 2 (HER2) is overexpressed in ∼25-30% of breast tumors. HER2-overexpressing breast tumors exhibit increased proliferation and metastasis, and subsequently, poor clinical prognosis. Presented here, is a novel mechanism for selective delivery of molecular EPRI probes to HER2-overexpressing breast tumor cells. We demonstrate bio-compatibility of EPRI probes we previously de...
Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presen...
Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients fo...
The expression status of human epidermal growth factor receptor type 2 (HER2) predicts the response ...
AbstractElectron paramagnetic resonance imaging (EPRI) allows detection and localization of paramagn...
Human epidermal growth factor receptor 2 (HER2) overexpression in breast cancers is associated with ...
Following the development of targeted therapies against EGFR and HER2, two members of the human epid...
Cell tracking could be useful to elucidate fundamental processes of cancer biology such as metastasi...
The optimal way to detect and treat cancer is to target cancer cells exclusively without affecting t...
Currently, breast cancer patients are classified uniquely according to the expression level of hormo...
<div><p>Following the development of targeted therapies against EGFR and HER2, two members of the hu...
Following the development of targeted therapies against EGFR and HER2, two members of the human epid...
Background/Aims: Smart molecular probes are required in the application of Magnetic resonance imagin...
The human epidermal growth factor receptor-2 (HER2) is overexpressed in 15-20% of breast cancer (BC)...
Purpose: Ovarian cancer (OC) leads to poor survival rates mainly due to late stage detection and inn...
The clinical utility of a human epidermal growth factor receptor 2 (HER2)–targeting Affibody molecul...
Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presen...
Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients fo...
The expression status of human epidermal growth factor receptor type 2 (HER2) predicts the response ...
AbstractElectron paramagnetic resonance imaging (EPRI) allows detection and localization of paramagn...
Human epidermal growth factor receptor 2 (HER2) overexpression in breast cancers is associated with ...
Following the development of targeted therapies against EGFR and HER2, two members of the human epid...
Cell tracking could be useful to elucidate fundamental processes of cancer biology such as metastasi...
The optimal way to detect and treat cancer is to target cancer cells exclusively without affecting t...
Currently, breast cancer patients are classified uniquely according to the expression level of hormo...
<div><p>Following the development of targeted therapies against EGFR and HER2, two members of the hu...
Following the development of targeted therapies against EGFR and HER2, two members of the human epid...
Background/Aims: Smart molecular probes are required in the application of Magnetic resonance imagin...
The human epidermal growth factor receptor-2 (HER2) is overexpressed in 15-20% of breast cancer (BC)...
Purpose: Ovarian cancer (OC) leads to poor survival rates mainly due to late stage detection and inn...
The clinical utility of a human epidermal growth factor receptor 2 (HER2)–targeting Affibody molecul...
Since its discovery, the human epidermal growth factor 2 (HER2) has been extensively studied. Presen...
Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients fo...
The expression status of human epidermal growth factor receptor type 2 (HER2) predicts the response ...